Therapeutic angiogenesis for critical limb ischemia

Seminars in Vascular Surgery

Volumn 27, Issue 1, 2014, Pages 23-31

  Ko, Sae Hee ^a   Bandyk, Dennis F ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLASMID DNA; SCATTER FACTOR; ANGIOGENIC FACTOR; ANGIOGENIC PROTEIN;

ANGIOGENESIS; BIOLOGICAL THERAPY; BONE MARROW; CELL THERAPY; CRITICAL LIMB ISCHEMIA; DIABETIC RETINOPATHY; DISEASE COURSE; FEASIBILITY STUDY; GENE; GENE THERAPY; GENE TRANSFER; HEMATOPOIETIC STEM CELL; HEPATOCYTE GROWTH FACTOR GENE; HUMAN; LEG REVASCULARIZATION; LONG TERM CARE; PATIENT SELECTION; PRIORITY JOURNAL; REVASCULARIZATION; REVIEW; STEM CELL TRANSPLANTATION; TISSUE REGENERATION; ANIMAL; BIOSYNTHESIS; BLOOD FLOW; CRITICAL ILLNESS; DISEASE MODEL; DRUG EFFECTS; GENETICS; ISCHEMIA; LIMB; METABOLISM; MULTIMODALITY CANCER THERAPY; PATHOPHYSIOLOGY; PROCEDURES; TREATMENT OUTCOME; VASCULARIZATION;

ANGIOGENESIS INDUCING AGENTS; ANGIOGENIC PROTEINS; ANIMALS; COMBINED MODALITY THERAPY; CRITICAL ILLNESS; DISEASE MODELS, ANIMAL; EXTREMITIES; GENETIC THERAPY; HUMANS; ISCHEMIA; NEOVASCULARIZATION, PHYSIOLOGIC; REGIONAL BLOOD FLOW; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME;

EID: 84925157072     PISSN: 08957967     EISSN: 15584518     Source Type: Journal    
DOI: 10.1053/j.semvascsurg.2014.10.001     Document Type: Review

References (38)

1. Norgen L., Hiatt W.R., Dormandy J.A., et al. Inter-society consensus for the management of peripheral arterial disease (TASC II). J Vasc Surg 2007, 45(Suppl S):S5-67.
2. Selvin E., Erlinger T.P. Prevalence of and risk factors for peripheral arterial disease in the United States: results from the National Health and Nutrition Examination Survey, 1999-2000. Circulation 2004, 10:738-743.
3. Lepantalo M., Matzke S. Outcome of unreconstructed chronic critical leg ischemia. Eur J Vasc Endovasc Surg 1996, 11:153-157.
4. Dormandy J., Heeck L., Vig S. The fate of patients with critical leg ischemia. Semin Vasc Surg 1999, 12:142-147.
5. Powell R.J. Update on clinical trials evaluating the effect of biologic therapy in patients with critical limb ischemia. J Vasc Surg 2012, 56:264-266.
6. Prostanoids for chronic critical limb ischemia. A randomized, controlled, open-label trial with prostaglandin E1. The ICAI Study Group. Ischemia Cronica degli Arti Inferiori. Ann Intern Med 1999, 130:412-421.
7. Brass E.P., Anthony R., Dormandy J., et al. Parenteral therapy with lipo-ecrapost, a lipid based formulation of a PGE1 analog does not alter six-month outcomes in patients with critical limb ischemia. J Vasc Surg 2006, 43:752-759.
8. Spincemaille G.H.J.J., de Vet H.C.W., Ubbink D.T., et al. The results of spinal chord stimulation in critical limb ischemia. A review. Eur J Vasc Endovasc Surg 2001, 21:99-105.
9. Shimamura M., Nakagami H., Koriyama H., et al. Gene therapy and cell-based therapies for therapeutic angiogenesis in peripheral artery disease. Biomed Res Int 2013, 2013:1-8.
10. Shweiki D., Itin A., Soffer D., et al. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 1992, 359(6398):843-845.
11. Comerata A.J., Throm R.C., Miller K.A., et al. Naked plasmid DNA encoding fibroblast growth factor type 1 for the treatment of end-stage unreconstructable lower extremity ischemia: preliminary results of a phase I trial. J Vasc Surg 2002, 35:930-936.
12. Palmer-Kazen U., Wariaro D., Luo F., et al. Vascular endothelial cell growth factor and fibroblast growth factor 2 expression in patients with critical limb ischemia. J Vasc Surg 2004, 39:621-628.
13. Shigematsu H., Yasuda K., Iwai T., et al. Randomized, double-blind, placebo-controlled clinical trial of hepatocyte growth factor plasmid for critical limb ischemia. Gene Ther 2010, 17:1152-1161.
14. Powell R., Goodney P., Mendelsohn P.O., et al. Safety and efficacy of patient specific intramuscular injection of HGF plasmid gene therapy on limb perfusion and wound healing in patients with ischemic lower extremity ulceration: results of the HGF-0205 trial. J Vasc Surg 2010, 52:1525-1530.
15. Morishita R., Makino H., Motokuni A., et al. Hepatocyte growth factor gene transfer to treat critical limb ischemia. Arterioscler Thromb Vasc Biol 2011, 31:713-720.
16. Fowkes F.G.R., Price J.F. Gene therapy for critical limb ischemia: the TAMARIS trial. Lancet 2011, 377:1894-1896.
17. Powell R., Simons M., Mendelsohn P.O., et al. Results of a double-blind, placebo-controlled study to assess the safety of intramuscular injection of hepatocyte growth factor plasmid to improve limb perfusion in patients with critical limb ischemia. Circulation 2008, 118:58-65.
18. Liew A., O'Brien T. Therapeutic potential for mesenchymal stem cell transplantation for critical limb ischemia. Stem Cell Res Ther 2012, 3:28-31.
19. Chamberlain G., Fox J., Ashton B., et al. Concise review: mesenchymal stem cells: their phenotype, differentiation capacity, immunological features, and potential for homing. Stem Cells 2007, 25:2739-2749.
20. Asahara T., Murohara T., Sullivan A., et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science 1997, 275:964-967.
21. Pittenger M.F., Mackay A.M., Beck S.C., et al. Multilineage potential of adult human mesenchymal stem cells. Science 1999, 284:143-147.
22. Ko S.H., Nauta A., Wong V., et al. The role of stem cells in cutaneous wound healing: what do we really know?. Plast Reconstr Surg 2011, 127(Suppl 1):10S-20S.
23. Kasper G., Dankert N., Tuischer J., et al. Mesenchymal stem cells regulate angiogenesis according to their mechanical environment. Stem Cells 2007, 25:903-910.
24. Grayson W.L., Zhao F., Bunnell B., et al. Hypoxia enhances proliferation and tissue formation of human mesenchymal stem cells. Biochem Biophys Res Commun 2007, 358:948-953.
25. Kalka C., Masuda H., Takahashi T., et al. Transplantation of ex vivo expanded endothelial progenitor cells for therapeutic neovascularization. Proc Natl Acad Sci U S A 2000, 97:3422-3427.
26. Aicher A., Heeschen C., Mildner-Rihm C., et al. Essential role of endothelial nitric oxide synthase for mobilization of stem and progenitor cells. Nat Med 2003, 9:1370-1376.
27. Shintani S., Murohara T., Ikeda H., et al. Augmentation of postnatal neovascularization with autologous bone marrow transplantation. Circulation 2001, 103:897-903.
28. Tateishi-Yuyama E., Matsubara H., Murohara T., et al. Therapeutic angiogenesis for patients with limb ischaemia by autologous transplantation of bone-marrow cells: a pilot study and a randomised controlled trial. Lancet 2002, 360:427-435.
29. Matoba S., Tatsumi T., Murohara T., et al. Long-term clinical outcome after intramuscular implantation of bone marrow mononuclear cells (Therapeutic Angiogenesis by Cell Transplantation [TACT] trial) in patients with chronic limb ischemia. Am Heart J 2008, 156:1010-1018.
30. Walter D.H., Krankenberg H., Balzer J.O., et al. Intraarterial administration of bone marrow mononuclear cells in patients with critical limb ischemia: a randomized-start, placebo-controlled pilot trial (PROVASA). Circ Cardiovasc Interv 2010, 4:26-37.
31. Ledford K.J., Murphy N., Ziegler F., et al. Potential beneficial effects of ixmyelocel-T in the treatment of atherosclerotic diseases. Stem Cell Res Ther 2013, 4:135.
32. Powell R.J., Comerota A.J., Berceli S.A., et al. Interim analysis results from the RESTORE-CLI, a randomized, double-blind multicenter phase II trial comparing expanded autologous bone marrow-derived tissue repair cells and placebo in patients with critical limb ischemia. J Vasc Surg 2012, 54:1032-1041.
33. Benoit E., O'Donnell T.F., Iafrati M.D., et al. The role of amputation as an outcome measure in cellular therapy for critical limb ischemia: implications for clinical trial design. J Transl Med 2011, 9:165.
34. Iafrati M.D., Hallett J.W., Geils G., et al. Early results and lessons learned from a multicenter, randomized, double-blind trial of bone marrow aspirate concentrate in critical limb ischemia. J Vasc Surg 2011, 54:1650-1658.
35. Chung J., Modrall J.G., Valentine R.J. The need for improved risk stratification in chronic limb ischemia. J Vasc Surg 2014 Sep 8, pii: S0741-5214(14)01485-2. 10.1016/j.jvs.2014.07.104, [Epub ahead of print].
36. Adam D.J., Beard J.D., Cleveland T., et al. Bypass versus angioplasty in severe ischaemia of the leg (BASIL): multicentre, randomised controlled trial. Lancet 2005, 366:1925-1934.
37. Teraa M., Sprengers R.W., van der Graaf Y., et al. Autologous bone marrow-derived cell therapy in patients with critical limb ischemia: a meta-analysis of randomized controlled clinical trials. Ann Surg 2013, 258:922-929.
38. Tomita N., Morishita R., Taniyama Y., et al. Angiogenic property of hepatocyte growth factor is dependent on upregulation of essential transcription factor for angiogenesis, ets-1. Circulation 2003, 107:1411-1417.